ABCL | AbCellera Biologics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	0.46
Implied Volatility	103.58%
IV Rank	47.56%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-11

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	18.56
EPS	N/A
1YR Price Target	28.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	586
Country	Canada
Website	ABCL

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

ABCL's peers: CWBR, HEPA, RAIN, KRYS, AVRO, CVAC, RETA, VIR, PPCB, PTCT, SRPT, IOVA, MDGL, CGC

*Chart delayed

Analyzing fundamentals for ABCL we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is very good and Health is weak. For more detailed analysis please see ABCL Fundamentals page.

Watching at ABCL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABCL Technicals page.